1,077 results

#111568-AAV5

Ready-to-use AAV5 particles produced from pZac2.1-GfaABC1D-mCherry-hPMCA2w/b (#111568). In addition to the viral particles, you will also receive purified pZac2.1-GfaABC1D-mCherry-hPMCA2w/b plasmid DNA. GfaABCD1-driven, expression of mCherry fused plasma membrane calcium pump hPMCA2w/b. These AAV preparations are suitable purity for injection into animals.

Baljit Khakh

Yu et al Neuron. 2018 Aug 27. pii: S0896-6273(18)

Feb. 14, 2022

Academic Institutions and Nonprofits only

#172907-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-Volton2-ST-WPRE (#172907). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-Volton2-ST-WPRE plasmid DNA. Cre-dependent, Syn-driven expression of the voltage sensor Voltron2-ST containing a soma localization targeting sequence. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Abdelfattah et al Neuron. 2023 Mar 28:S0896-6273(23)00205-

July 21, 2023

Academic Institutions and Nonprofits only

#50459-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-DIO-mCherry (#50459). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-mCherry plasmid DNA. hSyn-driven, Cre-dependent mCherry-expression control. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Feb. 3, 2020

Academic Institutions and Nonprofits only

#100843-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.GCaMP6s.WPRE.SV40 (#100843). In addition to the viral particles, you will also receive purified pAAV.Syn.GCaMP6s.WPRE.SV40 plasmid DNA. Syn-driven GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

March 19, 2018

Academic Institutions and Nonprofits only

#26973-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn-hChR2(H134R)-EYFP (#26973). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-EYFP plasmid DNA. hSyn-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 7, 2018

Academic Institutions and Nonprofits only

#65014-AAV8

Ready-to-use AAV8 particles produced from pAAV-hsyn-Jaws-KGC-GFP-ER2 (#65014). In addition to the viral particles, you will also receive purified pAAV-hsyn-Jaws-KGC-GFP-ER2 plasmid DNA. hSyn-driven Jaws-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Oct. 13, 2017

Academic Institutions and Nonprofits only

#105545-AAV9

Ready-to-use AAV9 particles produced from pAAV.CMV.HI.eGFP-Cre.WPRE.SV40 (#105545). In addition to the viral particles, you will also receive purified pAAV.CMV.HI.eGFP-Cre.WPRE.SV40 plasmid DNA. CMV-driven EGFP-Cre expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#105558-AAV9

Ready-to-use AAV9 particles produced from pENN.AAV.CamKII 0.4.Cre.SV40 (#105558). In addition to the viral particles, you will also receive purified pENN.AAV.CamKII 0.4.Cre.SV40 plasmid DNA. CamKII-driven Cre expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

July 30, 2018

Academic Institutions and Nonprofits only

#107790-AAV9

Ready-to-use AAV9 particles produced from AAV.CamKII.GCaMP6s.WPRE.SV40 (#107790). In addition to the viral particles, you will also receive purified AAV.CamKII.GCaMP6s.WPRE.SV40 plasmid DNA. CamKII-driven GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

May 15, 2018

Academic Institutions and Nonprofits only

#50465-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Oct. 24, 2016

Academic Institutions and Nonprofits only

#174007-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-jGCaMP8s-P2A-ChrimsonR-ST (#174007). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-jGCaMP8s-P2A-ChrimsonR-ST plasmid DNA. Syn-driven, Cre-dependent expression of calcium sensor GCaMP8s and soma-targeted ChrimsonR. These AAV preparations are suitable purity for injection into animals.

Mark Histed

LaFosse et al eNeuro. 2023 Mar 29;10(3):ENEURO.0378-22

May 4, 2023

Academic Institutions and Nonprofits only

#106174-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSynapsin.SF-iGluSnFR.A184S (#106174). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.A184S plasmid DNA. hSynapsin driven SF-iGluSnFR.A184S glutamate sensor. The A184S mutant has a higher glutamate affinity. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 14, 2024

Academic Institutions and Nonprofits only

#26973-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-hSyn-hChR2(H134R)-EYFP (#26973). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-EYFP plasmid DNA. hSyn-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 8, 2020

Academic Institutions and Nonprofits only

#50455-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-DIO-HA-hM4D(Gi)-IRES-mCitrine (#50455). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-HA-hM4D(Gi)-IRES-mCitrine plasmid DNA. Synapsin-driven, Cre-dependent, inhibitory hM3D DREADD expression, with physically separate mCitrine expression for cell body labeling. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Sept. 20, 2018

Academic Institutions and Nonprofits only

#114471-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO mCherry (#114471). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO mCherry plasmid DNA. Ef1a-driven, Flp recombinase-dependent expression of mCherry. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Aug. 28, 2020

Academic Institutions and Nonprofits only

#50476-AAV5

Ready-to-use AAV5 particles produced from pAAV-CaMKIIa-hM3D(Gq)-mCherry (#50476). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hM3D(Gq)-mCherry plasmid DNA. CaMKIIa-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Nov. 21, 2016

Academic Institutions and Nonprofits only

#73178-LV

Ready-to-use Lentiviral Prep particles produced from Human sgRNA library Brunello in lentiGuide-Puro (#73178). In addition to the viral particles, you will also receive purified Human sgRNA library Brunello in lentiGuide-Puro plasmid DNA. Ready-to-use lentiviral pooled library for CRISPR screening in human cells. Use on cells that are stably expressing Cas9 to make edits across 19,114 genes in the human genome.

John Doench, David Root

Doench et al Nat Biotechnol. 2016 Jan 18. doi: 10.103

Aug. 16, 2016

Academic Institutions and Nonprofits only

#100843-AAV9

Ready-to-use AAV9 particles produced from pAAV.Syn.GCaMP6s.WPRE.SV40 (#100843). In addition to the viral particles, you will also receive purified pAAV.Syn.GCaMP6s.WPRE.SV40 plasmid DNA. Syn-driven GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

March 19, 2018

Academic Institutions and Nonprofits only

#107708-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin- soCoChR-GFP (#107708). In addition to the viral particles, you will also receive purified pAAV-hSynapsin- soCoChR-GFP plasmid DNA. Synapsin-driven somatic CoChR (soCoChR) fused to GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Shemesh et al Nat Neurosci. 2017 Dec;20(12):1796-1806.

Sept. 7, 2018

Academic Institutions and Nonprofits only

#121675-AAV5

Ready-to-use AAV5 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Sept. 27, 2024

Academic Institutions and Nonprofits only

#213917-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_GCaMP6f (#213917). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_GCaMP6f plasmid DNA. Expression of GCaMP6f under the control of the Lamp5 interneuron-targeting enhancer E3. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#218792-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiLAMP5e3_dTomato_nlsdTomato (#218792). In addition to the viral particles, you will also receive purified pAAV_BiLAMP5e3_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the Lamp5 interneuron-targeting enhancer. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#51502-AAV1

Ready-to-use AAV1 particles produced from AAV pCAG-FLEX-EGFP-WPRE (#51502). In addition to the viral particles, you will also receive purified AAV pCAG-FLEX-EGFP-WPRE plasmid DNA. CAG-driven, Cre dependent EGFP expression control. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

March 7, 2018

Academic Institutions and Nonprofits only

#50458-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-DIO-rM3D(Gs)-mCherry (#50458). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-rM3D(Gs)-mCherry plasmid DNA. hSyn-driven, Cre-dependent rM3D(Gs) receptor with an mCherry reporter for chemogenetic excitation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 6, 2022

Academic Institutions and Nonprofits only

#125712-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE (#125712). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa(0.4)-eOPN3-mScarlet-WPRE plasmid DNA. CaMKIIa-driven expression of the optimized mosquito OPN3 rhodopsin in-frame with mScarlet. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Neuron. 2021 May 10. pii: S0896-6273(21)

June 26, 2024

Academic Institutions and Nonprofits only

#28306-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-FLEX-tdTomato (#28306). In addition to the viral particles, you will also receive purified pAAV-FLEX-tdTomato plasmid DNA. CAG-driven, Cre-dependent tdTomato expression control. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Feb. 28, 2018

Academic Institutions and Nonprofits only

#83898-AAV1

Ready-to-use AAV1 particles produced from pAAV-mDlx-ChR2-mCherry-Fishell-3 (#83898). In addition to the viral particles, you will also receive purified pAAV-mDlx-ChR2-mCherry-Fishell-3 plasmid DNA. mDlx-driven expression of ChR2, fused to mCherry. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 9, 2020

Academic Institutions and Nonprofits only

#176751-AAV5

Ready-to-use AAV5 particles produced from AAV-CamKIIa-jGCaMP8m-WPRE (#176751). In addition to the viral particles, you will also receive purified AAV-CamKIIa-jGCaMP8m-WPRE plasmid DNA. CamKIIa-driven expression of calcium sensor GCaMP8m. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Jan. 25, 2024

Academic Institutions and Nonprofits only

#59171-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Syn-ChrimsonR-tdT (#59171). In addition to the viral particles, you will also receive purified pAAV-Syn-ChrimsonR-tdT plasmid DNA. Syn-driven ChrimsonR-tdTomato expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Nov. 13, 2025

Academic Institutions and Nonprofits only

#176750-AAV1

Ready-to-use AAV1 particles produced from AAV-CamKIIa-jGCaMP8f-WPRE (#176750). In addition to the viral particles, you will also receive purified AAV-CamKIIa-jGCaMP8f-WPRE plasmid DNA. CamKIIa-driven expression of calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Loren Looger

June 8, 2023

Academic Institutions and Nonprofits only

#104061-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-CAG-NLS-GFP (#104061). In addition to the viral particles, you will also receive purified pAAV-CAG-NLS-GFP plasmid DNA. CAG-driven NLS-GFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

March 5, 2019

Academic Institutions and Nonprofits only

#114469-AAV5

Ready-to-use AAV5 particles produced from pAAV-CaMKIIa-mCherry (#114469). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-mCherry plasmid DNA. CamKIIa-driven expression of mCherry. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Aug. 28, 2020

Academic Institutions and Nonprofits only

#20298-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 12, 2017

Academic Institutions and Nonprofits only

#26976-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-hChR2(H134R)-mCherry (#26976). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-mCherry plasmid DNA. Synapsin-driven, humanized channelrhodopsin H134R mutant, fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Jan. 26, 2021

Academic Institutions and Nonprofits only

#27056-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO EYFP (#27056). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO EYFP plasmid DNA. EF1a-driven, cre-dependent EYFP expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 16, 2018

Academic Institutions and Nonprofits only

#162377-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-FLEX-jGCaMP8s-WPRE (#162377). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP8s-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of calcium sensor GCaMP8s (more sensitive). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Zhang et al Janelia Research Campus, Online Resource

April 26, 2021

Academic Institutions and Nonprofits only

#104488-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-syn-jGCaMP7f-WPRE (#104488). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7f-WPRE plasmid DNA. Synapsin-driven GCaMP7f calcium sensor. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Feb. 23, 2018

Academic Institutions and Nonprofits only

#171027-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO-ChrimsonR-tdTomato (#171027). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-ChrimsonR-tdTomato plasmid DNA. Flp-dependent, Ef1a-driven expression of ChrimsonR-tdTomato fusion for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

June 26, 2024

Academic Institutions and Nonprofits only

#50465-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Aug. 20, 2024

Academic Institutions and Nonprofits only

#176759-AAV9

Ready-to-use AAV9 particles produced from pZac2.1-GfaABC1D-lck-jGCaMP8f (#176759). In addition to the viral particles, you will also receive purified pZac2.1-GfaABC1D-lck-jGCaMP8f plasmid DNA. GfaABC1D-driven expression of membrane-bound calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only